Lockheed Martin Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Lockheed Martin Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,860	Closed	-$4.83M	–	119
2025 Q2	$4.83M	Buy	10,860 +2,760	+34%	+$1.27M	0.18%	79
2025 Q1	$3.93M	Sell	8,100 -190	-2%	-$88.5K	0.16%	81
2024 Q4	$3.34M	Sell	8,290 -1,660	-17%	-$769K	0.13%	85
2024 Q3	$4.63M	Buy	+9,950	New	+$4.78M	0.21%	70
2021 Q1	–	Sell	-24,320	Closed	-$5.75M	–	90
2020 Q4	$5.75M	Buy	24,320 +8,500	+54%	+$1.95M	0.3%	63
2020 Q3	$4.3M	Buy	+15,820	New	+$4.36M	0.27%	56
2019 Q3	–	Sell	-33,950	Closed	-$6.22M	–	94
2019 Q2	$6.22M	Buy	33,950 +18,950	+126%	+$3.31M	0.28%	82
2019 Q1	$2.76M	Buy	+15,000	New	+$2.77M	0.13%	81
2018 Q3	–	Sell	-4,100	Closed	-$697K	–	84
2018 Q2	$697K	Sell	4,100 -1,200	-23%	-$186K	0.03%	72
2018 Q1	$864K	Buy	+5,300	New	+$866K	0.04%	96
2015 Q3	–	Sell	-9,500	Closed	-$1.17M	–	132
2015 Q2	$1.17M	Sell	9,500 -26,800	-74%	-$3.38M	0.06%	88
2015 Q1	$4.28M	Buy	+36,300	New	+$4.35M	0.21%	50

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Lockheed Martin Investment Management's VRTX Position: Q3 2025 in Review

Lockheed Martin Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 10,860 shares — an estimated $4.83M sold.

Lockheed Martin Investment Management first reported a position in VRTX in Q1 2015 and held it in 12 quarters. The position peaked at $6.22M in Q2 2019. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

Lockheed Martin Investment Management reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Lockheed Martin Investment Management sold 10,860 Vertex Pharmaceuticals shares in Q3 2025, an estimated $4.83M.
Lockheed Martin Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 12 quarters.
Lockheed Martin Investment Management's Vertex Pharmaceuticals position peaked at $6.22M in Q2 2019.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Lockheed Martin Investment Management's 13F filing for Q3 2025, filed 30 Oct 2025.